Drug Sponsors

J. Michael Pearson returns, but Valeant hits SEC trouble

Tuesday, March 1, 2016

Valeant Pharmaceuticals International has announced that J. Michael Pearson returned as Valeant’s chief executive officer following his recovery from severe pneumonia and other complications, effective immediately. Howard B. Schiller, Valeant’s interim chief executive officer, will transition out of his current duties but will continue as a member of Valeant’s Board of Directors. Robert A. Ingram has been appointed chairman of the Board as the company has separated the roles of chairman and chief executive officer.

[Read More]

OSE Pharma, Effimune to merge

Friday, February 26, 2016

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration phase III study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, have announce the signing of a proposed merger agreement.

[Read More]

Unique patient center is opening lines of communication

Monday, February 22, 2016

A first-of-its-kind initiative to enhance communication between patient groups, the medical science industry and clinical research institutions has bloomed in Illinois, with the hope that the concept will broaden throughout the country to help produce better medical innovation outcomes.

[Read More]

AVROBIO launches in Cambridge, Massachusetts

Friday, February 19, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has announced its launch plans. The company’s priority is to accelerate development of two novel cell and gene therapies pioneered within the labs of Dr. Christopher Paige and Dr. Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.

[Read More]

Biogen joins Center for Therapeutic Target Validation

Wednesday, February 10, 2016

Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

[Read More]

ERT opening Innovation Lab in Boston

Monday, February 8, 2016

ERT is launching an Innovation Lab in Boston on February 9. A cloud platform solutions provider, ERT supplies the industry, sponsors and CROs alike, with technology, services and consultancy. The company is known for first-in-the-industry features such as wireless eDiaries to collect electronic Clinical Outcome Assessments (eCOA).

[Read More]